Paul Nathan, MBBS, PhD, MCRP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01-positive uveal melanoma.
Paul Nathan, MBBS, PhD, MCRP
Advertisement
Articles by Paul Nathan, MBBS, PhD, MCRP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Zongertinib Yields Enduring Activity in Frontline HER2+ NSCLC Trial
2
Novel Drug Class is Convenient and Meaningful in Multiple Myeloma Landscape
3
Dose Modification Strategies in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
4
Utilizing AI Algorithms to Inform Breast Cancer Chemoprevention Strategies
5